Hernandez-Lozano I, Mairinger S, Filip T, Lobsch M, Stanek J, Kuntner C
Antimicrob Agents Chemother. 2023; 67(3):e0149322.
PMID: 36786609
PMC: 10019293.
DOI: 10.1128/aac.01493-22.
Davary Avareshk A, Jalal R, Gholami J
Med Oncol. 2022; 39(12):194.
PMID: 36071289
DOI: 10.1007/s12032-022-01787-9.
Ince I, Dallmann A, Frechen S, Coboeken K, Niederalt C, Wendl T
J Clin Pharmacol. 2021; 61 Suppl 1:S70-S82.
PMID: 34185905
PMC: 8361729.
DOI: 10.1002/jcph.1869.
Schlender J, Teutonico D, Coboeken K, Schnizler K, Eissing T, Willmann S
Clin Pharmacokinet. 2018; 57(12):1613-1634.
PMID: 29737457
PMC: 6267540.
DOI: 10.1007/s40262-018-0661-6.
Guo T, Huang J, Zhang H, Dong L, Guo D, Guo L
Sci Rep. 2016; 6:32244.
PMID: 27572343
PMC: 5004175.
DOI: 10.1038/srep32244.
Intestinal ciprofloxacin efflux: the role of breast cancer resistance protein (ABCG2).
Haslam I, Wright J, OReilly D, Sherlock D, Coleman T, Simmons N
Drug Metab Dispos. 2011; 39(12):2321-8.
PMID: 21930826
PMC: 3226371.
DOI: 10.1124/dmd.111.038323.
Is Ciprofloxacin a Substrate of P-glycoprotein?.
Park M, Okochi H, Benet L
Arch Drug Inf. 2011; 4(1):1-9.
PMID: 21572514
PMC: 3084506.
DOI: 10.1111/j.1753-5174.2010.00032.x.
Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs.
Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W
J Pharmacokinet Pharmacodyn. 2007; 34(3):401-31.
PMID: 17431751
DOI: 10.1007/s10928-007-9053-5.
Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.
Schrickx J, Fink-Gremmels J
Br J Pharmacol. 2007; 150(4):463-9.
PMID: 17211460
PMC: 2189727.
DOI: 10.1038/sj.bjp.0706974.
A mechanistic approach for the scaling of clearance in children.
Edginton A, Schmitt W, Voith B, Willmann S
Clin Pharmacokinet. 2006; 45(7):683-704.
PMID: 16802850
DOI: 10.2165/00003088-200645070-00004.
Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males.
Stass H, Kubitza D, Moller J, Delesen H
Br J Clin Pharmacol. 2005; 59(5):536-41.
PMID: 15842551
PMC: 1884843.
DOI: 10.1111/j.1365-2125.2005.02357.x.
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Yamaguchi H, Yano I, Saito H, Inui K
Pharm Res. 2004; 21(2):330-8.
PMID: 15032316
DOI: 10.1023/b:pham.0000016247.44589.f1.
Multiple pathways for fluoroquinolone secretion by human intestinal epithelial (Caco-2) cells.
Lowes S, Simmons N
Br J Pharmacol. 2002; 135(5):1263-75.
PMID: 11877335
PMC: 1573224.
DOI: 10.1038/sj.bjp.0704560.
Evaluation of the influence of antacids and H2 antagonists on the absorption of moxifloxacin after oral administration of a 400mg dose to healthy volunteers.
Stass H, Bottcher M, Ochmann K
Clin Pharmacokinet. 2001; 40 Suppl 1:39-48.
PMID: 11352441
DOI: 10.2165/00003088-200140001-00006.
Active intestinal elimination of ciprofloxacin in rats: modulation by different substrates.
Dautrey S, Felice K, Petiet A, Lacour B, Carbon C, Farinotti R
Br J Pharmacol. 1999; 127(7):1728-34.
PMID: 10455332
PMC: 1566149.
DOI: 10.1038/sj.bjp.0702703.
Influence of renal failure on intestinal clearance of ciprofloxacin in rats.
Dautrey S, Rabbaa L, Laouari D, Lacour B, Carbon C, Farinotti R
Antimicrob Agents Chemother. 1999; 43(3):678-80.
PMID: 10049287
PMC: 89180.
DOI: 10.1128/AAC.43.3.678.
Secretion of sparfloxacin from the human intestinal Caco-2 cell line is altered by P-glycoprotein inhibitors.
Cormet-Boyaka E, Huneau J, Mordrelle A, Boyaka P, Carbon C, Rubinstein E
Antimicrob Agents Chemother. 1998; 42(10):2607-11.
PMID: 9756763
PMC: 105905.
DOI: 10.1128/AAC.42.10.2607.
Influence of renal failure on ciprofloxacin pharmacokinetics in rats.
Veau C, Dautrey S, Tod M, Laouari D, Carbon C, Farinotti R
Antimicrob Agents Chemother. 1998; 42(2):289-92.
PMID: 9527774
PMC: 105402.
DOI: 10.1128/AAC.42.2.289.
Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract.
van den Hazel S, de Vries X, Speelman P, Dankert J, Tytgat G, Huibregtse K
Antimicrob Agents Chemother. 1996; 40(11):2658-60.
PMID: 8913485
PMC: 163596.
DOI: 10.1128/AAC.40.11.2658.
Intestinal elimination of ofloxacin enantiomers in the rat: evidence of a carrier-mediated process.
Rabbaa L, Dautrey S, Colas-Linhart N, Carbon C, Farinotti R
Antimicrob Agents Chemother. 1996; 40(9):2126-30.
PMID: 8878593
PMC: 163485.
DOI: 10.1128/AAC.40.9.2126.
